Pertussis: An Underappreciated Risk for Nosocomial Outbreaks

David J. Weber, MD, MPH; William A. Rutala, PhD, MPH

Between 1988 and 1996, the number of cases of pertussis reported in the United States has ranged between 2,719 and 7,796, considerably higher than levels reported between 1976 and 1980. The highest attack rate of pertussis occurs in children <1 year of age, but approximately 25% of cases reported in 1996 were in persons ≥15 years of age. Pertussis is highly contagious; secondary attack rates exceed 80% among highly susceptible household contacts. Pertussis is a worldwide problem; the World Health Organization estimated that in 1994 approximately 40 million cases occurred worldwide, with 360,000 children dying.

PERTUSSIS IN THE ADULT

Recent studies have shed new light on the epidemiology of pertussis in the adult. Studies using serology for diagnosis have found that pertussis is a common cause of prolonged cough (i.e., >2 weeks) in the adult. Household studies have demonstrated a high attack rate in homes with infected children and that adults may serve as the index case. In one study of 257 adult pertussis cases in 121 families, the following symptoms were reported: cough, 91%; any cough >21 days, 80%; spasmodic cough >21 days, 63%; sleep disturbed by coughing, 52%; cough followed by choking or vomiting, 53%; whoop, 8%. Compared with children, the following symptoms are less common in adults: facial flushing due to cough, cough-induced vomiting, whoop, and cyanosis with cough. Subclinical pertussis may be common in adults with household exposures. Adults with mild respiratory disease have transmitted infection to children. Studies of pertussis in adults suggest that the common belief that life-long immunity follows Bordetella pertussis infection is incorrect and that reinfection is common in both previously vaccinated and non-vaccinated persons. Additionally, studies in adults have demonstrated that culture alone is insensitive for the diagnosis of pertussis.

Adolescents and young adults play an important role in the transmission of pertussis, because immunization-induced immunity to pertussis wanes with increasing age and disease in adults frequently is not diagnosed or treated because it is often mild or atypical.

PERTUSSIS IN HEALTHCARE FACILITIES

In this issue, Haiduven and colleagues report that their institution had 49 pertussis exposures over a 9-year period from 1989 to 1997. Our experience is similar: 40 employees were exposed to 15 patients with pertussis from 1994 to 1997. Multiple outbreaks of pertussis in healthcare facilities have been reported in the literature. The median number of patients with pertussis was 38 (range, 2-107); of symptomatic staff, 5 (range, 4-41); and of infected staff, 7 (range, 5-42). However, during one large community outbreak, pertussis occurred in 87 employees. These outbreaks have resulted from failure to recognize and isolate infected infants and children, failure to recognize and treat disease in staff members, and failure to institute control measures rapidly. A cohort study of healthcare workers in which pertussis serology was determined every 6 months demonstrated frequent pertussis infection. The Centers for Disease Control and Prevention (CDC) and infectious disease experts recommend the following guidelines for managing pertussis exposures: (1) isolate suspected or known infected patients using Droplet Precautions; (2) provide postexposure prophylaxis for all asymptomatic
exposed employees; (3) evaluate all symptomatic employees for pertussis, and provide appropriate therapy; and (4) furlough symptomatic employees during the first 5 days of their therapy. Haiduven and colleagues have provided a valuable guide for infection control professionals by publishing their detailed protocols for managing pertussis exposures. In addition to following CDC guidelines, Haiduven and coworkers have instituted the following interventions: (1) exposed asymptomatic healthcare workers are required to wear a mask whenever caring for a child under the age of 4 years, until 5 days of chemoprophylaxis have been completed, and (2) exposed healthcare workers who refuse prophylaxis must mask from 7 days after the first possible date of exposure until 14 days after the last possible date of exposure to a case of pertussis. As the authors note, this approach is more conservative than that recommended by the CDC. Haiduven and associates recommend the following antibiotics (in order of preference): erythromycin 500 mg qid for 14 days, clarithromycin 500 mg bid for 14 days, azithromycin (no dose or duration listed), oxytetracycline 500 mg qid for 14 days, or trimethoprim-sulfamethoxazole 1 DS bid for 14 days. Because erythromycin at this dose and duration frequently causes gastrointestinal irritation, we preferentially use clarithromycin or azithromycin. Although oxytetracycline has in the past proved successful in treating pertussis, in vitro studies suggest only modest to good activity. In accordance with recommendations published in the Red Book, the primary alternative for macrolide-intolerant healthcare workers is trimethoprim-sulfamethoxazole.

PROBLEMS WITH IMPLEMENTING INFECTION CONTROL POLICIES TO CONTROL PERTUSSIS

There are several important problems with implementing policies to minimize nosocomial transmission of pertussis. First, many physicians are not familiar with the manifestations of pertussis, especially in adults. Hence, the diagnosis frequently is missed, leading to failure to institute proper isolation and therapy. Second, currently available tests such as direct fluorescent antibody and culture lack sensitivity and specificity and are rarely positive in adults who have been symptomatic for more than 2 weeks. Detection of antibody using acute and convalescent sera is an important research tool but has little applicability for rapid detection and therapy. Third, currently available pertussis vaccines are not recommended for persons aged \( \geq 7 \) years. Fourth, erythromycin, the only drug currently approved by the Food and Drug Administration (FDA) for pertussis, requires qid dosing for 2 weeks. Gastrointestinal toxicity frequently limits its use in healthcare workers. Fifth, only limited data are available on the rates of acquisition of pertussis by healthcare personnel, risks of transmission, and success of currently recommended infection control measures.

RECENT ADVANCES

Fortunately, several areas of recent research may allow improved prevention and management of nosocomial pertussis. Educating pediatricians, internists, and healthcare workers regarding the resurgence of pertussis and the recognition of pertussis in adults is being accomplished by recent editorials and reviews. Methods for educating healthcare workers have been described. The forms produced by Haiduven and colleagues are likely to be very useful in the education of healthcare workers regarding the detection and management of patients with pertussis.

Erythromycin is the only drug approved by the FDA for the treatment of pertussis; the estolate form is preferred by some clinicians because of superior pharmacokinetics. B pertussis is highly susceptible in vitro to erythromycin. Erythromycin has been shown to decrease the duration of illness when administered early in the course of pertussis and to eliminate B pertussis from the nasopharynx. For these reasons, erythromycin is considered the drug of choice for the treatment and prophylaxis of pertussis. Erythromycin therapy of infected persons plus chemoprophylaxis of exposed persons has been used successfully to reduce secondary spread in households or to terminate outbreaks in healthcare institutions. The potential epidemiological flaws in clinical trials of erythromycin prophylaxis have been reviewed. Of concern, erythromycin-resistant isolates of B pertussis have been isolated occasionally from clinical specimens in the United States. B pertussis is also susceptible in vitro to trimethoprim-sulfamethoxazole, the newer macrolides azithromycin and clarithromycin, and the quinolones levofloxacin, ciprofloxacin, and ofloxacin. Trimethoprim-sulfamethoxazole has been demonstrated to be effective therapy in small clinical trials and therefore is the recommended alternative for treatment of chemoprophylaxis of individuals intolerant to erythromycin. However, its efficacy as a chemoprophylactic agent has not been evaluated. Small clinical trials suggest that clarithromycin and azithromycin also are effective for the treatment of pertussis. Although older studies had suggested that a 14-day course of erythromycin therapy was required for eradication of B pertussis, recent trials have suggested that the following shorter courses of antibiotics are as successful as the standard 14-day course of erythromycin: 7 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g), 7 days of clarithromycin, or 5 days of azithromycin. Because of the high frequency of gastrointestinal intolerance with erythromycin, we—like Haiduven and colleagues—have switched to one of the newer macrolides.

DTaP vaccine (diphtheria, tetanus toxoid, acellular pertussis) is now approved for all pediatric age groups. Studies have shown acellular pertussis vaccine to be safer and at least as effective as whole-cell vaccine. The DTaP vaccines will need to be reformulated for use in
adults, because all infant formulations contain more diphtheria toxoid than is recommended for persons aged ≥7 years.49 Small clinical trials suggest that acellular pertussis vaccine elicits a good antibody response and is safe when provided to adults.51,52 Acellular pertussis vaccine has been used to aid in containing nosocomial outbreaks.41 Large-scale trials in adults are underway. Introduction of booster immunizations for adults has been recommended if ongoing trials demonstrate the acellular vaccine to be safe and effective in adults.53

New diagnostic tests are being used now to study the epidemiology of pertussis.54 The polymerase chain reaction (PCR) is sensitive and specific,55,56 but if introduced into clinical use will require increased technician time.57 PCR has been used to document nosocomial acquisition of pertussis.58 In erythromycin-treated subjects, PCR has been shown to demonstrate B pertussis after cultures turned negative.59 It is likely that, in the next decade, the diagnosis of pertussis will be made by using a combination of methods including direct fluorescent antibody, culture, PCR, and serology; the exact tests chosen will depend on the patient population, treatment status, and duration of symptoms.54

RESEARCH NEEDS

Future research should be undertaken to establish the risk of nosocomial acquisition of pertussis. The efficacy of the new macrolides, especially when used in short courses as postexposure prophylaxis, should be studied, because they would be tolerated much better than erythromycin. If acellular pertussis vaccine is demonstrated to be safe and effective in adults, additional studies should be undertaken to evaluate its efficacy in preventing nosocomial acquisition of pertussis by healthcare workers. Finally, improved diagnostic methods that have enhanced sensitivity and specificity without undue costs need to be validated and become commercially available for use by clinical microbiology laboratories.

REFERENCES


